德国某学术教学医院药物基因组学与药物相互作用筛查的临床实施及门诊随访
该研究在德国某学术医院建立60个基因变异面板的PGx检测与DDI筛查工作流,将CPIC/DPWG指南报告整合入EHR并向患者提供移动应用。255例患者中95%携带至少一个可操作PGx变异,21.5%获得可操作建议,其中75.5%被住院医师调整治疗;出院3个月随访显示全科医生在77%已调整用药患者中维持优化治疗。
要点
- 95%患者携带至少一个可操作PGx变异,最常见影响他汀、5-氟尿嘧啶、伊立替康和泮托拉唑。
- 21.5%患者获得可操作建议,住院医师据此调整治疗的比例为75.5%。
- 全科医生在77%住院期间调整用药的患者中维持优化治疗,仅1/10患者与全科医生讨论结果。
核心结论
- 在德国医院实施先发性PGx检测与DDI筛查可行,医师与全科医生接受度高,PGx整合入EHR有助于精准医学推广。
研究设计与样本
- 在德国某学术教学医院建立基于60个基因变异面板的PGx工作流,将CPIC/DPWG指南报告整合入EHR并通过移动与网页应用向患者提供。
- 纳入255例患者,出院3个月后通过用药档案与问卷评估基于PGx的决策。
主要发现
- 255例患者中95%携带至少一个可操作PGx变异,最常见影响他汀、5-氟尿嘧啶、伊立替康和泮托拉唑。
- 21.5%患者获得可操作建议,住院医师随后调整治疗的比例为75.5%。
- 识别57个临床显著DDI,其中21%涉及PGx药物。
- 住院期间启动用药调整的患者中,全科医生维持优化治疗的比例为77%。
- 1/10患者与全科医生讨论结果,全科医生支持未来处方中使用PGx并请求培训。
临床怎么用
- 可参考该工作流将PGx报告与DDI筛查整合入EHR,并向患者提供移动端结果查询。
- 对携带可操作PGx变异者,住院期间可依据CPIC/DPWG建议调整治疗并联动全科医生维持优化方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pharmacogenomics (PGx) helps to explain variability in drug response, including adverse drug reactions. Functional variants in genes affecting drug absorption, distribution, metabolism, and excretion (ADME) have been described. Despite PGx guidelines (e.g., CPIC and DPWG) enabling genotype-guided drug and dose selection, preemptive implementation remains challenging due to various issues including standardized result communication and integration into electronic health record (EHR) systems. We implemented PGx testing as well as drug-drug interaction (DDI) screening in a German academic hospital and assessed their impact on physicians, general practitioners (GPs), and patients. A novel PGx workflow was established using a 60-genetic variant panel. CPIC/DPWG guideline-based PGx reports were integrated into the EHR system and provided as a mobile and web application for patients through a genetic information system. Medication profiles and questionnaires evaluated PGx-based decisions 3 months post-discharge. Among 255 patients, 95% had at least one actionable PGx variant, most commonly affecting statins, 5-fluorouracil, irinotecan, and pantoprazole. Actionable recommendations were provided in 21.5%, with hospital physicians modifying treatment subsequently in 75.5%. We identified 57 clinically significant DDIs, including PGx drugs in 21%. GPs maintained optimized treatment in 77% of those patients with a medication change initiated during hospitalization. One in 10 patients discussed results with their GPs. GPs favored PGx for future prescriptions and requested training. We showed that preemptive PGx testing can be successfully implemented in a German hospital with high acceptance among physicians and GPs, and that PGx integration into the EHR supports broader adoption in precision medicine.
引用
- Tremmel R, Schreeck F, Jaeger S, et al. Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up. Clin Pharmacol Ther. 2025. PMID: 41074844. doi:10.1002/cpt.70083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。